Cargando…
Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
Autores principales: | Niswander, Lisa M., Loftus, Joseph P, Lainey, Élodie, Caye-Eude, Aurélie, Pondrom, Morgane, Hottman, David A., Iacobucci, Ilaria, Mullighan, Charles G., Jain, Nitin, Konopleva, Marina, Cavé, Hélène, Baruchel, André, Rohrlich, Pierre S., Tasian, Sarah K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485673/ https://www.ncbi.nlm.nih.gov/pubmed/34196168 http://dx.doi.org/10.3324/haematol.2021.278697 |
Ejemplares similares
-
Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia
por: Brethon, Benoît, et al.
Publicado: (2021) -
Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021) -
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
por: Lopes, Bruno A., et al.
Publicado: (2022) -
Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021) -
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)